NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
4.910
+0.060 (1.24%)
At close: Nov 13, 2026, 4:00 PM EST
4.940
+0.030 (0.61%)
After-hours: Nov 13, 2026, 7:30 PM EST
NeOnc Technologies Holdings Employees
NeOnc Technologies Holdings had 5 employees as of December 31, 2025. The number of employees decreased by 3 or 37.50% compared to the previous year. That makes NeOnc Technologies Holdings the 41,917th largest employer in the world and 6,486th in the United States.
Employees
5
Change
-3
Growth
-37.50%
Revenue / Employee
$7,998
Profits / Employee
-$9,171,643
Market Cap
136.36M
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Codexis | 146 |
| Voyager Therapeutics | 141 |
| Molecular Partners AG | 134 |
| Nkarta | 103 |
| Immunic | 100 |
| enGene Therapeutics | 82 |
| Unicycive Therapeutics | 22 |
NTHI News
- 21 hours ago - NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach - GlobeNewsWire
- 1 day ago - NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial - GlobeNewsWire
- 1 day ago - NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations - GlobeNewsWire
- 2 days ago - FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track - GlobeNewsWire
- 2 days ago - NeOnc granted Type B End-of-Phase meeting by FDA for intranasal NEO100 - TheFly
- 2 days ago - NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 - GlobeNewsWire
- 4 days ago - NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues - GlobeNewsWire
- 8 days ago - NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - GlobeNewsWire